Related Experiment Video
Updated: Mar 23, 2026
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Overcoming Resistance to EGFR Inhibitors in NSCLC
Paolo Maione1, Paola C Sacco, Francesca Casaluce
1Paolo Maione, MD, Division of Medical Oncology, "S. G. Moscati" Hospital, Avellino, Italy. pmaione@libero.it.
Background:
The clarification of several molecular pathways underlying the tumorigenesis has led to the development of several targeted drugs that have substantially improved the treatment of Non-Small-Cell Lung Cancer (NSCLC). The Epidermal Growth Factor Receptor (EGFR) is the target of several Tyrosine-Kinase Inhibitors (TKIs), some of them approved for treatment and others currently in clinical development. EGFR-TKIs markedly improve progression-free survival of patients with advanced NSCLC with EGFR mutations compared with chemotherapy.
Methods:
We undertook a structured search of bibliographic databases for peer-reviewed research literature using a focused review question.
Results:
Although first- and second-generation agents offer in target population (with EGFR mutations) a substantial improvement of outcomes compared with standard chemotherapy, unfortunately, drug resistance develops after initial benefit, through a variety of mechanisms. Novel- (third) generation EGFR inhibitors have a selective mechanism of action and are currently in advanced clinical development, producing encouraging results in patients with acquired resistance to previous generation agents.
Conclusion:
The search for new drugs or strategies to overcome the TKI resistance in patients with EGFR mutations is to be considered a priority for the improvement of outcomes in the treatment of advanced NSCLC, and third-generation EGFR inhibitors are the most promising approach to the issue.
Insights
Targeted therapies like Epidermal Growth Factor Receptor (EGFR) Tyrosine-Kinase Inhibitors (TKIs) improve outcomes for Non-Small-Cell Lung Cancer (NSCLC) patients with EGFR mutations. Third-generation EGFR inhibitors show promise in overcoming drug resistance.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Targeted therapies have significantly advanced Non-Small-Cell Lung Cancer (NSCLC) treatment.
- Epidermal Growth Factor Receptor (EGFR) Tyrosine-Kinase Inhibitors (TKIs) are key drugs targeting specific mutations in NSCLC.
- EGFR-TKIs improve progression-free survival in advanced NSCLC patients with EGFR mutations compared to chemotherapy.
Purpose of the Study:
- To review the efficacy of EGFR-TKIs in treating NSCLC.
- To explore mechanisms of drug resistance to EGFR-TKIs.
- To evaluate the potential of novel EGFR inhibitors in overcoming resistance.
Main Methods:
- A structured literature search of bibliographic databases was performed.
- Peer-reviewed research on EGFR-TKI treatment in NSCLC was analyzed.
- Focus was placed on studies addressing drug resistance and novel therapeutic strategies.
Main Results:
- First- and second-generation EGFR-TKIs offer substantial benefits for patients with EGFR mutations.
- Acquired drug resistance is a significant challenge, limiting long-term efficacy.
- Third-generation EGFR inhibitors demonstrate encouraging results in patients with acquired resistance.
Conclusions:
- Overcoming TKI resistance in EGFR-mutated NSCLC is a priority.
- Third-generation EGFR inhibitors represent a promising strategy to improve treatment outcomes.
- Continued research into novel drugs and strategies is essential for advancing NSCLC care.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Related Concept Videos
02:56Treatment Resistant Cancers
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistent Cancers